Evidence map›Paper›PMID 21940174›Full record

ArticleBioorganic & medicinal chemistry2011

A sucrose-derived scaffold for multimerization of bioactive peptides.

Venkataramanarao Rao, Ramesh Alleti, Liping Xu, Narges K Tafreshi, David L Morse, Robert J Gillies, Eugene A Mash

Open access · bronzeAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Biochimica et biophysica acta. Molecular basis of disease · 2017
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Venkataramanarao RaoDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85721-0041, USA.
Ramesh Alleti
Liping Xu
Narges K Tafreshi
David L Morse
Robert J Gillies
Eugene A Mash
Moffitt Cancer Center · USUniversity of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Multimeric Ligands for Targeting of MelanomaR01CA097360 · NCI · UNIVERSITY OF ARIZONA · PI HRUBY, VICTOR J, MORSE, DAVID L · 2003 to 2012
$5.5M
Targeting Pancreatic CancerR01CA123547 · NCI · UNIVERSITY OF ARIZONA · PI MORSE, DAVID L · 2007 to 2011
$3.0M
Multimeric Ligands for Targeting of Pancreatic CancerR33CA095944 · NCI · UNIVERSITY OF ARIZONA · PI GILLIES, ROBERT J. · 2003 to 2005
$1.6M
Multimeric Ligands for Targeting of Pancreatic CancerR21CA095944 · NCI · UNIVERSITY OF ARIZONA · PI GILLIES, ROBERT J · 2002 to 2002
$152k
NCI NIH HHS P30 CA023074NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA 23074NCI NIH HHS R01 CA097360NCI NIH HHS R01 CA 123547NCI NIH HHS R01 CA123547NCI NIH HHS R01 CA 97360NCI NIH HHS R21 CA095944NCI NIH HHS R33 CA095944NCI NIH HHS R33 CA 95944
6 · The paper itself

Abstract

A spherical molecular scaffold bearing eight terminal alkyne groups was synthesized in one step from sucrose. One or more copies of a tetrapeptide azide, either N(3)(CH(2))(5)(CO)-His-DPhe-Arg-Trp-NH(2) (MSH4) or N(3)(CH(2))(5)(CO)-Trp-Met-Asp-Phe-NH(2) (CCK4), were attached to the scaffold via the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. Competitive binding assays using Eu-labeled probes based on the superpotent ligands Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-Lys-Pro-Val-NH(2) (NDP-α-MSH) and Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH(2) (CCK8) were used to study the interactions of monovalent and multivalent MSH4 and CCK4 constructs with Hek293 cells engineered to overexpress MC4R and CCK2R. All of the monovalent and multivalent MSH4 constructs exhibited binding comparable to that of the parental ligand, suggesting that either the ligand spacing was inappropriate for multivalent binding, or MSH4 is too weak a binder for a second 'anchoring' binding event to occur before the monovalently-bound construct is released from the cell surface. In contrast with this behavior, monovalent CCK4 constructs were significantly less potent than the parental ligand, while multivalent CCK4 constructs were as or more potent than the parental ligand. These results are suggestive of multivalent binding, which may be due to increased residence times for monovalently bound CCK4 constructs on the cell surface relative to MSH4 constructs, the greater residence time being necessary for the establishment of multivalent binding.

Indexed as

Protein MultimerizationAlkynesBinding, CompetitiveCell Cycle ProteinsCell LineMagnetic Resonance SpectroscopyMolecular StructureRegression AnalysisSolid-Phase Synthesis TechniquesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSucroseTetragastrinAlkynesCell Cycle ProteinsMSH4 protein, humanSucroseTetragastrin

Identifiers

PMID21940174
PMCPMC3197697
OpenAlexW2075039815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.